Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AYALA PHARMACEUTICALS, INC.

(AYLA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
9.84(c) 10.21(c) 10.1(c) 10.01(c) 10(c) Last
39 648 2 805 3 745 120 038 46 626 Volume
-1.70% +3.76% -1.08% -0.89% -0.10% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 3,52 M - -
Net income 2021 -41,6 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,37x
Yield 2021 -
Sales 2022 3,60 M - -
Net income 2022 -54,2 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,60x
Yield 2022 -
Capitalization 131 M 131 M -
Capi. / Sales 2021 37,2x
Capi. / Sales 2022 36,4x
Nbr of Employees 34
Free-Float 45,3%
More Financials
Company
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company. The Company is focused on developing and commercializing small molecule therapeutics for patients suffering from rare cancers. The Company's portfolio of product candidates includes, AL101 and AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. Its product candidates AL101 and AL102, are developed as... 
More about the company
Ratings of Ayala Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about AYALA PHARMACEUTICALS, INC.
09/23AYALA PHARMACEUTICALS : Announces Publication Highlighting Clinical Activity of its Gamma ..
AQ
09/23Ayala Pharmaceuticals, Inc. Announces Publication Highlighting Clinical Activity of Its..
CI
09/16AYALA PHARMACEUTICALS : Says Phase 2 Trial Shows AL101 Demonstrates 'Meaningful' Clinical ..
MT
09/16AYALA PHARMACEUTICALS, INC. : Other Events (form 8-K)
AQ
09/16AYALA PHARMACEUTICALS : Presents Preliminary Clinical Data from the Ongoing Phase 2 ACCURA..
AQ
09/16Ayala Pharmaceuticals, Inc. Announces Pre-Clinical Proof of Concept Data for Enhanced A..
CI
09/02AYALA PHARMACEUTICALS : to Participate in Upcoming Virtual Investor Conferences
AQ
09/01Ayala Pharmaceuticals to Present Clinical Data from Ongoing Phase 2 ACCURACY Trial and ..
GL
08/17AYALA PHARMACEUTICALS : Oppenheimer Adjusts Ayala Pharmaceuticals PT to $25 From $27, Main..
MT
08/13Ayala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Busine..
GL
08/13Ayala Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Sec..
CI
08/12AYALA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Re..
AQ
07/30AYALA PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
07/30Todd Sone Resigns from the Board of Directors of Ayala Pharmaceuticals, Inc
CI
07/13AYALA PHARMACEUTICALS : Ladenburg Thalmann Initiates Coverage on Ayala Pharmaceuticals Wit..
MT
More news
News in other languages on AYALA PHARMACEUTICALS, INC.
09/16Ayala affirme que l'essai de phase 2 montre que l'AL101 présente une activité clinique ..
2020AYALA PHARMACEUTICALS : en hausse, un broker prudent
2020AYALA PHARMACEUTICALS : Jefferies commence à 'Conserver'
More news
Analyst Recommendations on AYALA PHARMACEUTICALS, INC.
More recommendations
Chart AYALA PHARMACEUTICALS, INC.
Duration : Period :
Ayala Pharmaceuticals, Inc. Technical Analysis Chart | AYLA | US05465V1089 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 10,00 $
Average target price 22,33 $
Spread / Average Target 123%
EPS Revisions
Managers and Directors
Roni Mamluk President, Chief Executive Officer & Director
Yossi Maimon Chief Financial Officer, Secretary & Treasurer
David Sidransky Chairman
Gary Gordon Chief Medical Officer
Joel Kaye VP-Research & Nonclinical Development
Sector and Competitors
1st jan.Capi. (M$)
AYALA PHARMACEUTICALS, INC.-9.09%131
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414